Adaptive Biotechnologies Corp
NASDAQ:ADPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Adaptive Biotechnologies Corp
Pre-Tax Income
Adaptive Biotechnologies Corp
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
Pre-Tax Income
-$59.5m
|
CAGR 3-Years
33%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Pre-Tax Income
$7.4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
14%
|
|
|
Danaher Corp
NYSE:DHR
|
Pre-Tax Income
$4.3B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
8%
|
|
|
Waters Corp
NYSE:WAT
|
Pre-Tax Income
$754.9m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Pre-Tax Income
$1.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Pre-Tax Income
$1.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
34%
|
CAGR 10-Years
11%
|
|
Adaptive Biotechnologies Corp
Glance View
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.
See Also
What is Adaptive Biotechnologies Corp's Pre-Tax Income?
Pre-Tax Income
-59.5m
USD
Based on the financial report for Dec 31, 2025, Adaptive Biotechnologies Corp's Pre-Tax Income amounts to -59.5m USD.
What is Adaptive Biotechnologies Corp's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
16%
Over the last year, the Pre-Tax Income growth was 63%. The average annual Pre-Tax Income growth rates for Adaptive Biotechnologies Corp have been 33% over the past three years , 16% over the past five years .
